Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.
FLYING Magazine on MSN
Improving Safety in Part 91 Flying Through SOPs
While standard operating procedures in Part 91 may be voluntary, adopting them is a critical step in professionalizing your ...
Executive Chair Chung emphasizes customer-focused transformation and ecosystem strengthening to navigate evolving market ...
The Express Tribune on MSN
New navigation aid installed in DI Khan
The Pakistan Airports Authority (PPA) has successfully completed the commissioning of a state-of-the-art Doppler VHF ...
Key PointsMarathon Petroleum Corporation (MPC) was named to the Women In Trucking Association's 2025 Top Companies for Women ...
An important work from a rediscovered artist has been absent from public view since the 1970s. A New York curator is hunting ...
Since yachts first raced, getting a favorable rating for your race-boat has been an indulgence, verging on obsession, for ...
12don MSN
Inside the Danish royal family’s heartwarming Christmas with King Frederik, Queen Mary and children
It has been an especially full and public December for King Frederik, Queen Mary, and their four children, Crown Prince Christian, Princess Isabella, and twins Prince Vincent and Princess Josephine, ...
thesun.ng on MSN
Nigeria’s navigational aids fully functional – NAMA
By Chinelo ObogoThe Nigerian Airspace Management Agency (NAMA) has said that all navigational aids (NAVAIDs) at the Federal Government airports across Nigeria are fully functional and compliant with ...
In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...
Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results